Dignitana is a Swedish medical technology company listed on Nasdaq First North Growth Market in Stockholm.
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. Dignitana AB headquarters are in Lund, Sweden with operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy.
Short Name: DIGN
Nasdaq First North Growth Market: Dignitana
Important information about First North
Nasdaq First North Growth Market is an alternative marketplace run by the various stock exchanges included in Nasdaq. It has the same legal status as a regulated exchange. Companies on Nasdaq First North Growth Market are regulated by Nasdaq First North Growth Market’s rules and not by the legal requirements that are demanded for trading on a regulated exchange. An investment in a company that is traded on Nasdaq First North Growth Market carries more risk than an investment in a company listed on a regulated exchange. All companies, whose stock is listed for trading on Nasdaq First North Growth Market have a Certified Advisor who assures that all regulations are observed. Nasdaq Stockholm AB approves applications to be included in trading on Nadaq First North Growth Market.
For more than ten years Nasdaq First North Growth Market has served as an important growth platform, enabling Nordic and international entrepreneurs to access growth capital to develop and expand their businesses. There is a well-functioning ecosystem surrounding Nasdaq First North Growth Market, with advisers facilitating a smooth listing process and a range of investors supporting the market, from retail investors to institutional capital.
The total number of outstanding shares is 48,599,155.
The share has been listed on the Nasdaq First North Growth Market since 30 November 2011 after having been listed at Aktietorget since June 2009.
There are 265,000 warrants issued in the company. The warrants carry the right to purchase 165,000 shares in the period June 1 to 30, 2019 and 100,000 shares in the period June 1 to 30, 2020 and will, on full exercise, increase the company share capital by SEK 265,000.
Please note that the content of this website is not intended as professional medical or healthcare advice and should not be construed as a substitute for professional healthcare advice, or services from a qualified professional healthcare provider familiar with your unique situation. This content is intended solely as a general product and corporate information.
10925 Estate Lane, Suite 185
Dallas, TX 75238
226 60 Lund, Sweden
+46 46 16 30 90